Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) had its price target decreased by Royal Bank Of Canada from $71.00 to $58.00 in a research note released on Monday morning. Royal Bank Of Canada currently has an outperform rating on the stock.

TEVA has been the topic of several other reports. Goldman Sachs Group Inc. dropped their price target on shares of Teva Pharmaceutical Industries from $70.00 to $60.00 in a research report on Sunday, July 17th. Mizuho reaffirmed a buy rating on shares of Teva Pharmaceutical Industries in a research report on Sunday, July 17th. HSBC raised shares of Teva Pharmaceutical Industries from a hold rating to a buy rating in a research report on Monday, July 18th. Zacks Investment Research raised shares of Teva Pharmaceutical Industries from a sell rating to a hold rating in a research report on Monday, July 18th. Finally, Maxim Group reaffirmed a buy rating on shares of Teva Pharmaceutical Industries in a research report on Monday, July 18th. Thirteen analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company’s stock. Teva Pharmaceutical Industries presently has a consensus rating of Buy and an average target price of $60.00.

Teva Pharmaceutical Industries (NYSE:TEVA) traded up 0.87% during mid-day trading on Monday, reaching $38.40. 837,740 shares of the company’s stock traded hands. Teva Pharmaceutical Industries has a 1-year low of $37.25 and a 1-year high of $66.55. The firm has a 50 day moving average of $42.97 and a 200 day moving average of $49.87. The firm has a market cap of $35.10 billion, a PE ratio of 25.65 and a beta of 0.73.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Tuesday, November 15th. The company reported $1.31 EPS for the quarter, topping the Zacks’ consensus estimate of $1.29 by $0.02. The business had revenue of $5.56 billion for the quarter, compared to analyst estimates of $5.71 billion. Teva Pharmaceutical Industries had a net margin of 7.56% and a return on equity of 17.77%. The firm’s revenue for the quarter was up 15.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.35 earnings per share. Analysts forecast that Teva Pharmaceutical Industries will post $5.16 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 20th. Investors of record on Monday, December 5th will be issued a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a yield of 3.57%. Teva Pharmaceutical Industries’s dividend payout ratio (DPR) is presently 58.39%.

A number of hedge funds have recently added to or reduced their stakes in the stock. Natixis increased its stake in shares of Teva Pharmaceutical Industries by 62.0% in the first quarter. Natixis now owns 5,197 shares of the company’s stock valued at $278,000 after buying an additional 1,988 shares during the period. Schonfeld Strategic Advisors LLC bought a new stake in shares of Teva Pharmaceutical Industries during the first quarter valued at approximately $2,241,000. Samlyn Capital LLC increased its stake in shares of Teva Pharmaceutical Industries by 18.5% in the first quarter. Samlyn Capital LLC now owns 1,954,175 shares of the company’s stock valued at $104,568,000 after buying an additional 305,662 shares during the period. Panagora Asset Management Inc. increased its stake in shares of Teva Pharmaceutical Industries by 216.5% in the first quarter. Panagora Asset Management Inc. now owns 702,480 shares of the company’s stock valued at $37,590,000 after buying an additional 480,509 shares during the period. Finally, Bridger Management LLC bought a new stake in shares of Teva Pharmaceutical Industries during the first quarter valued at approximately $59,320,000. 63.00% of the stock is owned by institutional investors and hedge funds.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules.

5 Day Chart for NYSE:TEVA

Receive News & Stock Ratings for Teva Pharmaceutical Industries Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Ltd. and related stocks with our FREE daily email newsletter.